Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Archer-Daniels-Midland Company

Air Products and Chemicals

Enbridge

UnitedHealth Group

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks.

5 Relatively Secure And Cheap Dividend Stocks To Invest In - April 2024

Moderna

Pfizer

With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one's buck. For new investors seeking reasonable valuations and overlooked long-term growth drivers, the biotech scene is worth considering.

The 3 Most Undervalued Biotech Stocks to Buy in April 2024

The U.S. Food and drug Administration on Friday allowed use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer.

U.S. FDA allows expanded use of Bristol Myers' cell therapy

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #CART--U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma.

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Johnson & Johnson

Merck

Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.

Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.

Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion

PRINCETON N.J.--(BUSINESS WIRE)---- $BMY #COMMANDS--European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent.

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESG--Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company's meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company's ESG strategy is embedded in its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. “For more than 130 years, BMS has enabled positive change for our patients around the w.

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

Bristol-Myers Squibb has expected 2024 annual revenue of $45.85B and expected annual earnings per share of $6.83. BMY is currently below its 10-month exponential moving average (EMA), indicating bearish price action. However, there are signs of institutional accumulation, short-term bullish momentum, and potential improvement in relative strength.

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

CVS Health

Walgreens

Three well-known companies stand out among the market's complexity as excellent opportunities for investors looking for significant gains. Each company operates in the broad domains of pharmaceuticals and healthcare, positioning it strategically to take advantage of new trends and consumer needs.

The Bargain Hunter's Dream: 3 Underpriced Stocks Poised for Massive Gains

Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.

Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study

Zai Lab Ltd.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--  Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer   Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) partner Bristol Myers Squibb (NYSE: BMY) announced the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monother.

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic

AbbVie

Canadian Natural Resources

Essential Properties Realty Trust Inc

Extra Space Storage

Interpublic Group of Companies

Coca-Cola Femsa SAB de CV

NextEra Energy

SPDR S&P 500 ETF Trust

Sempra Energy

I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for consideration.

10 Dividend Growth Stocks: March 2024

Halozyme Therapeutics

Eli Lilly

Biotech is an industry full of opportunity. It's also known as one of the riskiest sectors to invest in.

The 3 Best Biotech Stocks to Buy in Q2 2024

Bristol Myers Squibb's market capitalization has declined significantly due to the impending expiration of patents for its flagship drugs. Bristol Myers Squibb's high debt levels add to the financial strain, requiring strategic measures to survive and maintain its position in the market. But I'd not prematurely bury BMY's prospects: Perhaps growth is not exactly what this stock is worth buying for, but the value it holds seems to be more durable.

Bristol Myers Squibb: The Comeback Is Unfolding

Bristol Myers Squibb said on Thursday its experimental drug to treat Crohn's disease, a chronic inflammatory bowel condition, failed to meet the main goal in a late-stage study.

Bristol Myers' bowel disease drug fails to meet main goal in late-stage study

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #KRAZATI--Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint.

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Crohns--BMS Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia in Patients with Moderately to Severely Active Crohn's Disease.

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.

Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts

AMN Healthcare Services

Patterson Companies

Royalty Pharma

Semler Scientific

Voyager Therapeutics

With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #bloodcancer--Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes.

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

AstraZeneca

Bayer AG

Bicycle Therapeutics Plc - ADR

Exelixis

Fusion Pharmaceuticals

Novartis

Takeda Pharmaceutical

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

2 More Potential Biotech Buyout Targets

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024.

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.

Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion

PRINCETON N.J.--(BUSINESS WIRE)---- $BMY #Abecma--BMS' Abecma Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory.

Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

News for Bristol-Myers Stock (BMY)